Cell Therapy News

Fludarabine exposure appeared associated with improved clinical outcomes among pediatric patients undergoing chimeric antigen receptor T-cell therapy for refractory or relapsed B-cell acute lymphoblastic leukemia, study results showed.

Brenda M. Sandmaier, MD, has been named the 2022-2023 president of American Society for Transplantation and Cellular Therapy.

Ira Braunschweig, MD, has been appointed as section chief of transplant and cell therapy at Rutgers Cancer Institute of New Jersey.

More than half of patients treated with tabelecleucel for Epstein-Barr virus-driven post-transplant lymphoproliferative disease responded to therapy, phase 3 study results showed.

The FDA granted orphan drug designation to ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma.

SALT LAKE CITY — Chimeric antigen receptor T-cell therapy appeared effective for patients with primary or secondary central nervous system large B-cell lymphoma, according to study results.

A bispecific chimeric antigen receptor T-cell therapy continues to show promising efficacy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma, results of a phase 1/phase 2 trial suggest.

SALT LAKE CITY — Patients with relapsed or refractory large B-cell lymphoma who failed chimeric antigen receptor T-cell therapy achieved durable responses with allogeneic hematopoietic stem cell transplantation, according to study results.

SALT LAKE CITY — Ciltacabtagene autoleucel induced a 95% overall response rate among patients with multiple myeloma who had early relapse after front-line therapy, according to results of a cohort analysis from the CARTITUDE-2 trial.

The FDA granted fast track designation to ADI-001 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.